Oracle Health Sciences applications has been chosen by DreamCIS, a contract research organization in Korea. DreamCIS required a clinical trial management system to replace its legacy clinical software solution and help enable the company’s biometrics center to become an Asian clinical trial data management hub.
DreamCIS intends to use Oracle Clinical and Oracle Remote Data Capture (RDC) 4.5.3 to help meet global standards for clinical trials data management and achieve higher quality local clinical trial services. DreamCIS is the first CRO in Korea to adopt the applications.
“Oracle’s proven experience in the health sciences sector was important to us and we believe their solutions will enable us to raise our data management levels to global standards, and help us become the leader in the Asian clinical trial markets in the future,” said Hee-Joong Koh, Director, Biometrics Center, DreamCIS.
Oracle RDC 4.5.3 uses the same data model as Oracle Clinical, ensuring tight integration of data between these applications. It is also completely Web-based, with a ‘zero client footprint’ for the HTML data entry window. This enables improved global access and performance for life sciences organizations to conduct global clinical studies more cost effectively whether using traditional pen and paper, electronic data capture, or hybrid methods.
“As the number of clinical trials increases in the Korean market and throughout Asia, there is a growing need for best-in-class software applications for clinical development and drug safety,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. “We are committed to helping emerging CROs like DreamCIS accelerate insights for better health and look forward to supporting their efforts to become an important hub for clinical data management in the region.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.